TrialCompass TCL
Back to results
Phase 2Not yet recruitingPriority 3 · Moderate priorityNCT07574528

A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is evaluating Sintilimab, Pegaspargase, and other medications as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Sintilimab (DRUG): Sintilimab will be given at 200 mg by intravenous infusion. | Pegaspargase (DRUG): Pegaspargase will be given at 2000 U/m², with a maximum total dose of 3750 U, by intramuscular injection. | Selinexor (DRUG): Selinexor will be given orally once weekly at 60mg. | radiotherapy (RADIATION): Patients will receive induction treatment for up to 4 cycles, followed by radiotherapy.

Drugs / treatments
Sintilimab, Pegaspargase, Selinexor, radiotherapy
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma

NCT07574528

Phase: Phase 2 | Status: Not yet recruiting | Priority: Medium

Plain-language summary

This Phase 2 trial is evaluating Sintilimab, Pegaspargase, and other medications as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

What's being tested

Sintilimab (DRUG): Sintilimab will be given at 200 mg by intravenous infusion. | Pegaspargase (DRUG): Pegaspargase will be given at 2000 U/m², with a maximum total dose of 3750 U, by intramuscular injection. | Selinexor (DRUG): Selinexor will be given orally once weekly at 60mg. | radiotherapy (RADIATION): Patients will receive induction treatment for up to 4 cycles, followed by radiotherapy.

Drugs / treatments: Sintilimab, Pegaspargase, Selinexor, radiotherapy

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 47 patients

Primary endpoint: Complete Response Rate (CRR)

Ages: 18 Years to —

Start date: 2026-05-06 | Est. completion: 2031-05-06

Locations

0 US sites · 1 total

Contact

Qingqing Cai | caiqq@sysucc.org.cn | +8618353201165

Sponsor: Sun Yat-sen University (OTHER)

Tags

ENKTL · Newly diagnosed

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07574528

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.